China Isotope & Radiation Corporation

Equities

1763

CNE1000031F4

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. Other stock markets 04:08:10 2024-05-21 am EDT			5-day change	1st Jan Change
11.02 ^HKD	-4.01%		-1.78%	-17.51%

Apr. 22	China Isotope & Radiation Corporation Announces First Carrier-Free Lutetium-177 GMP Production Line with Annual Production Capacity of 10,000-Curie GMP-Grade Lutetium-177	CI
Apr. 04	China Isotope & Radiation to Form JV Company	MT

China Isotope & Radiation Corporation Announces Establishment of Science and Technology Innovation Committee

December 23, 2022 at 08:46 am EST

The board of directors of China Isotope & Radiation Corporation announced that on 23 December 2022, the Board has resolved to establish the Science and Technology Innovation Committee under the Board, and appoint Mr. Wang Suohui, Mr. Xu Hongchao, Mr. Du Jin, Mr. Tian Jiahe and Mr. Lu Chuang as the members, and Mr. Wang Suohui as the chairman.

Latest news about China Isotope & Radiation Corporation

China Isotope & Radiation Corporation Announces First Carrier-Free Lutetium-177 GMP Production Line with Annual Production Capacity of 10,000-Curie GMP-Grade Lutetium-177	Apr. 22	CI
China Isotope & Radiation to Form JV Company	Apr. 04	MT
China Network Group Co., Ltd. Enters into the Investment and Cooperation Agreement with CNNC Hainan Nuclear Power	Apr. 03	CI
China Isotope & Radiation Corporation Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable Before 13 August 2024	Mar. 27	CI
China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
China Isotope & Radiation Corporation Announces Resignation of Chen Shoulei as Non-Executive Director, Vice Chairman, Members of the Strategy Committee, the Audit and Risk Management Committee and the Legal Affairs Committee of the Board	Mar. 27	CI
China Isotope & Radiation Breath Test Kit Gets a Clinical Approval Nod	Mar. 05	MT
China Isotope & Radiation Corporation Announces Approval by the National Medical Products Administration, Shenzhen Zhonghe Headway Bio-Sci & Tech Co. Ltd	Mar. 04	CI
China Isotope & Radiation Arm Secures Safety License for Production Facility in Xinjiang	Jan. 15	MT
China Isotope & Radiation Subsidiary Secures Compliance Accreditation	Jan. 03	MT
CIRC to Buy Radiation Processing Research and Technology Firm	Dec. 28	MT
China Isotope & Radiation Gets New Direct Controlling Shareholder	Dec. 27	MT
China Isotope & Radiation Corporation Elects Zhang Junqi as an Executive Director	Dec. 22	CI
China Isotope & Radiation Corporation Announces Resignation of Wang Suohui as Director	Dec. 21	CI
China Isotope's Nuclear Energy Project Gets 'Outstanding' Rating	Dec. 07	MT
CIRC Wins ESG Case Award in China	Dec. 07	MT
CIRC Boosts Capital Injection in Financial Company	Nov. 24	MT
China Isotope & Radiation Corporation Announces Executive Changes	Nov. 10	CI
China Isotope & Radiation Corporation Appoints Mr. Fan Guomin Employee Representative Director	Nov. 10	CI
CIRC Renews Multiple Agreements with Controlling Shareholder, Affiliates for Two Years	Nov. 01	MT
China Isotope & Radiation Corporation Enter into the Renewed Supply Agreement with China National Nuclear Corporation	23-10-31	CI
China Isotope & Radiation Corporation Enter into the Renewed Consulting Services FeeFramework Agreement with CNNC Tongxing Nuclear Technology Co., Ltd	23-10-31	CI
China Isotope & Radiation Corporation Enter into the Renewed Carbon-14 Supply Agreement with Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd	23-10-31	CI
China Isotope & Radiation to Sell In Vitro Diagnostic Reagents Firm	23-10-24	MT
CNNC Accuray's Tumor Imaging Device Obtains Registration, Manufacturing License in China	23-09-28	MT

Chart China Isotope & Radiation Corporation

Duration

Period

Chart China Isotope & Radiation Corporation

More charts

Company Profile

China Isotope & Radiation Corporation is a China-based company mainly engaged in research, development, manufacturing and sales of radiopharmaceuticals and radioactive source products. The Company operates mainly through five segments. The Pharmaceuticals segment is mainly engaged in the manufacture and sales of various radiopharmaceuticals for imaging diagnosis and treatment, urea breath test kits and testers, as well as in vitro diagnostic reagents and kits. The Radioactive Source Product segment is mainly engaged in the production and sales of various radioactive source products, and provides related technical services. The Irradiation segment mainly provides irradiation sterilization services and others. The Radiotherapy Equipment and Related Services segment is mainly engaged in the research and development of radiotherapy equipment. The Independent Medical Laboratory Services and Other Business segment mainly provides independent medical laboratory services.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
CHINA ISOTOPE & RADIATION CORPORATION	-17.51%	471M
BIOMÉRIEUX	-6.26%	12.23B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.93%	8.17B
DIASORIN S.P.A.	+7.10%	5.78B
LANTHEUS HOLDINGS, INC.	+30.16%	5.74B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.47%	4.24B
10X GENOMICS, INC.	-57.20%	2.97B
ANDON HEALTH CO., LTD.	+12.56%	2.73B
VITROLIFE AB	-4.67%	2.38B
MYRIAD GENETICS, INC.	+27.38%	2.26B

Diagnostic & Testing Substances